Production (Stage)
D
Fennec Pharmaceuticals Inc. FRX.TO
TSX
Recommendation
Prev Close
$11.15
Volume
--
Avg Vol (90D)
428
Market Cap
$226.47M
Dividend & Yield
--
52-Week Range
$5.65 - $12.11
P/E (TTM)
--
EPS (TTM)
-$0.5367
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
$30.91M
EBITDA (TTM)
-$11.88M
EBIT (TTM)
-$11.98M
Net Income (TTM)
-$14.44M
Balance Sheet
Total Assets (Q)
$46.40M
Total Debt (Q)
$19.35M
Total Liabilities (Q)
$52.28M
Book Value Per Share (Q)
-$0.2131
Cash Flow
Cash from Operations (TTM)
-$16.39M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
-$12.12M
Net Change in Cash (TTM)
-$28.51M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
0.70
7-Day Total Return
5.65%
30-Day Total Return
37.89%
60-Day Total Return
24.37%
90-Day Total Return
21.05%
Year to Date Total Return
29.99%
1-Year Total Return
25.43%
2-Year Total Return
1.20%
3-Year Total Return
71.37%
5-Year Total Return
2.08%
52-week Low
Nov 15, 2024 - $5.65
52-week High
Jun 09, 2025 - $12.11
Valuation
Market Cap
$226.47M - Micro Cap
Enterprise Value
$223.15M
Price/Sales (TTM)
9.95
Price/Book (Q)
-52.32
Dividends and Shares
Shares Outstanding
27.58M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
fennecpharma.com
Phone Number
919 636 4530
Address
68 TW Alexander Drive
Research Triangle Park, NC 27709
Country
United States
Year Founded
1996
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate... more